Scaffold Repurposing Reveals New Nanomolar Phosphodiesterase Type 5 (PDE5) Inhibitors Based on Pyridopyrazinone Scaffold: Investigation of In Vitro and In Silico Properties

• Päätekijät: Kamelia M. Amin (Tekijä), Ossama M. El-Badry (Tekijä), Doaa E. Abdel Rahman (Tekijä), Magda H. Abdellattif (Tekijä), Mohammed A. S. Abourehab (Tekijä), Mahmoud H. El-Maghrabey (Tekijä), Fahmy G. Elsaid (Tekijä), Mohamed A. El Hamd (Tekijä), Ahmed Elkamhawy (Tekijä), Usama M. Ammar (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: MDPI AG, 2022-09-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Inhibition of PDE5 results in elevation of cGMP leading to vascular relaxation and reduction in the systemic blood pressure. Therefore, PDE5 inhibitors are used as antihypertensive and antianginal agents in addition to their major use as male erectile dysfunction treatments. Previously, we developed...